FeesSafety
Pluang+

Allogene Therapeutics highlights allogeneic CAR T's potential to expand lymphoma patient access at ASH 2026.

Market News
20 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Allogene Therapeutics highlights allogeneic CAR T's potential to expand lymphoma patient access at ASH 2026.

Allogene Therapeutics announced its participation in the 2026 American Society of Hematology (ASH) Annual Meeting to showcase the potential of allogeneic CAR T therapy to improve patient access for large B-cell lymphoma (LBCL). The company will present new market research and host a physician panel discussing barriers to CAR T treatment and community adoption. Their pivotal ALPHA3 trial, evaluating cemacabtagene ansegedleucel (cema-cel) as a first-line consolidation therapy guided by minimal residual disease (MRD), will be featured at a clinical trial showcase. This effort aims to bring CAR T therapy earlier in treatment and closer to patients, potentially broadening its availability and adoption.

Allogene Therapeutics' upcoming events at the 2026 ASH Annual Meeting provide context for health sector activity on Pluang. As of Nov 20, 2026 19:11 WIB, 72 of 150 priced US health stocks rose while 71 fell. Notable movers include CRON at USD 2.99 with a -2.92% change and a typical hold time of 23 days, and ABCL at USD 10.20 with a -2.58% change and Pluang order activity showing 57% sell and 43% buy.

More News

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

Johnson & Johnson's TREMFYA (guselkumab) demonstrated significant improvements in spinal pain, stiffness, and MRI-confirmed inflammation in patients with axial psoriatic arthritis (PsA) in the Phase 4 STAR study. The study, the first of its kind usin...

Company Fundamentals
Bullish
48 minutes ago
Build a balanced portfolio with Vanguard Morningstar Growth ETF for growth and Schwab U.S. Dividend Equity ETF for income.

Build a balanced portfolio with Vanguard Morningstar Growth ETF for growth and Schwab U.S. Dividend Equity ETF for income.

Investors seeking both growth and income can consider a simple ETF portfolio combining the Vanguard Morningstar Growth ETF (VUG) and the Schwab U.S. Dividend Equity ETF (SCHD). VUG focuses on large-cap growth stocks, heavily weighted in technology, w...

Market News
Bullish
1 hour ago
Hyperliquid aims to become the Amazon of decentralized finance by scaling perpetual futures markets.

Hyperliquid aims to become the Amazon of decentralized finance by scaling perpetual futures markets.

Hyperliquid, a decentralized exchange specializing in perpetual futures contracts, is expanding its platform to include real-world assets and prediction markets, aiming to become the "house all of finance." It operates similarly to Amazon's marketpla...

Market News
Bullish
1 hour ago
Bitcoin plunges below $62,000 amid tech selloff, inflation fears, and largest crypto hack ever.

Bitcoin plunges below $62,000 amid tech selloff, inflation fears, and largest crypto hack ever.

Bitcoin has dropped below $62,000 after six consecutive weeks of decline, falling more than 50% from its October 2025 peak of around $126,000. The slide was triggered by a combination of factors including a tech sector selloff due to AI valuation con...

Bearish
1 hour ago
Rocket Lab beats sales estimates, backlog soars, and posts first positive operating cash flow quarter.

Rocket Lab beats sales estimates, backlog soars, and posts first positive operating cash flow quarter.

Rocket Lab reported Q3 sales of $268 million, beating estimates and marking a 73% year-over-year increase, with a backlog growing to $3.6 billion. Despite missing earnings expectations with a loss of $0.12 per share, the company achieved its first fu...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App